EUVIMEDEUVIMED entdecken
Crossref

Features of the disease-modifying antirheumatic drugs for rheumatoid arthritis in men depending on testosterone levels

T.S. Panevin, E.G. Zotkin, G.I. Gridneva, E.S. Matyushchenko, S.I. Glukhova

Russian Journal of Preventive Medicine · 05.08.2026 · 29 (7) · 68

DOI: 10.17116/profmed20262907168 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Russian Journal of Preventive Medicine, erschienen am 05.08.2026. Verfasst von T.S. Panevin und 4 weiteren Autor:innen. Die Arbeit nennt 17 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rheumatoid arthritis (RA) is associated with a high incidence of cardiovascular-kidney-metabolic conditions and hypogonadism syndrome in men.

Objective

To study the features of antirheumatic therapy in men with rheumatoid arthritis and concomitant hypogonadism. Materials and methods. A total cross-sectional study including 169 men with a confirmed diagnosis of RA was carried out. Total testosterone level was measured in all patients; hypogonadism was diagnosed when the total testosterone level amounted to ≤12.0 nmol/L. A subgroup comparison of indicators reflecting the course and activity of RA, administered therapy and presence of concomitant diseases was performed in men with normal and reduced testosterone levels.

Results

Patients with low testosterone level had similar RA duration, activity, and stage, but were less likely to receive methotrexate (26.8% versus 51.7%; p=0.006). Current duration of methotrexate administration or history of its intake was shorter in patients of the hypogonadism subgroup (1.0 [1.0; 3.0] year versus 3.0 [1.0; 7.0] years; p=0.027). In reduced testosterone level, a higher body mass index (31.0±4.0 kg/m2 and 26.1±3.7 kg/m2, respectively; p

Zitieren

APA

Panevin, T., Zotkin, E., Gridneva, G., Matyushchenko, E., & Glukhova, S. (2026). Features of the disease-modifying antirheumatic drugs for rheumatoid arthritis in men depending on testosterone levels. Russian Journal of Preventive Medicine, 29(7), 68. https://doi.org/10.17116/profmed20262907168

Vancouver

Panevin T, Zotkin E, Gridneva G, Matyushchenko E, Glukhova S. Features of the disease-modifying antirheumatic drugs for rheumatoid arthritis in men depending on testosterone levels. Russian Journal of Preventive Medicine. 2026;29(7):68. doi:10.17116/profmed20262907168

BibTeX
@article{Panevin2026,
  author = {Panevin, T.S. and Zotkin, E.G. and Gridneva, G.I. and Matyushchenko, E.S. and Glukhova, S.I.},
  title = {Features of the disease-modifying antirheumatic drugs for rheumatoid arthritis in men depending on testosterone levels},
  journal = {Russian Journal of Preventive Medicine},
  year = {2026},
  volume = {29},
  number = {7},
  pages = {68},
  doi = {10.17116/profmed20262907168}
}
Kostenlos starten →